8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Rodrigues Ferreira, Sylvie ^a   Di Tommasso, Anne ^a   Dimitrov, Ariane ^b   Cazaubon, Sylvie ^a   Gruel, Nadège ^c,d   Colasson, Hélène ^a   Nicolas, André ^e   Chaverot, Nathalie ^a   Molinié, Vincent ^f   Reyal, Fabien ^b   Sigal Zafrani, Brigitte ^d,e   Terris, Benoit ^g   Delattre, Olivier ^c,d   Radvanyi, François ^b   Rerez, Franck ^b   Vincent Salomon, Anne ^d,e   Nahmias, Clara ^a  

^a INSTITUT COCHIN   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT CURIE   (France)

^d INSTITUT CURIE   (France)

^e Pathology Department   (France)

^f SAINT JOSEPH HOSPITAL   (France)

^g NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL TUMOR SUPPRESSOR PROTEIN 1; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ATIP1 PROTEIN, MOUSE; CARRIER PROTEIN; MTUS1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; BREAST RECONSTRUCTION; CANCER CELL; CANCER CELL CULTURE; CANCER GRADING; CANCER INFILTRATION; CELL COUNT; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CENTROSOME; CHROMOSOME 8P; CLONOGENESIS; CONTROLLED STUDY; CYTOSKELETON; DISTANT METASTASIS; DOWN REGULATION; DRUG TARGETING; FEMALE; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METAPHASE; MICROTUBULE; MITOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CARCINOMA; CHROMOSOME 8; CHROMOSOME MAP; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; MOUSE MUTANT; ULTRASTRUCTURE;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CARRIER PROTEINS; CELL PROLIFERATION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MICE; MICE, SCID; MITOSIS; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 70349690097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007239     Document Type: Article

References (38)

1. Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14: 8019-8026.
2. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26: 2568-2581.
3. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
6. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
7. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541.
8. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, et al. (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45: 1033-1040.
9. Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, et al. (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67: 11565-11575.
10. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, et al. (2009) Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 7: 511-522.
11. Chin L, Gray JW (2008) Translating insights from the cancer genome into clinical practice. Nature 452: 553-563.
12. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, et al. (2001) Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 7: 876-882.
13. Seibold S, Rudroff C, Weber M, Galle J, Wanner C, et al. (2003) Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J 17: 1180-1182.
14. Pils D, Horak P, Gleiss A, Sax C, Fabjani G, et al. (2005) Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer 104: 2417-2429.
15. Lee S, Bang S, Song K, Lee I (2006) Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep 16: 747-754.
16. Ye H, Pungpravat N, Huang BL, Muzio LL, Mariggiò MA, et al. (2007) Genomic assessments of the frequent loss of heterozygosity region on 8p21.3 approximately p22 in head and neck squamous cell carcinoma. Cancer Genet Cytogenet 176: 100-106.
17. Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA (2006) Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet 38: 82-88.
18. Frank B, Bermejo JL, Hemminki K, Sutter C, Wappenschmidt B, et al. (2007) Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk. Carcinogenesis 28: 1442-1445.
19. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, et al. (2004) Trans-inactivation of receptor tyrosine kinases by novel AT2 receptor-interacting protein, ATIP. J Biol Chem 279: 28989-28997.
20. Di Benedetto M, Bièche I, Deshayes F, Vacher S, Nouet S, et al. (2006) Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene 380: 127-136.
21. Wruck CJ, Funke-Kaiser H, Pufe T, Kusserow H, Menk M, et al. (2005) Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol 25: 57-64.
22. Reyal F, Stransky N, Bernard-Pierrot I, Vincent-Salomon A, de Rycke Y, et al. (2005) Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes-a study of 130 invasive ductal breast carcinomas. Cancer Res 65: 1376-1383.
23. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, et al. (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26: 3153-3158.
24. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, et al. (2008) Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 14: 1956-1965.
25. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.
26. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
27. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96.
28. Coombs LM, Pigott D, Proctor A, Eydmann M, Denner J, et al. (1990) Simultaneous isolation of DNA, RNA, and antigenic protein exhibiting kinase activity from small tumor samples using guanidine isothiocyanate. Anal Biochem 188: 338-343.
29. Nizak C, Martin-Lluesma S, Moutel S, Roux A, Kreis TE, et al. (2003) Recombinant antibodies against subcellular fractions used to track endogenous Golgi protein dynamics in vivo. Traffic 4: 739-753.
30. Dimitrov A, Paupe V, Gueudry C, Sibarita JB, Raposo G, et al. (2009) The gene responsible for Dyggve-Melchior-Clausen syndrome encodes a novel peripheral membrane protein dynamically associated with the Golgi apparatus. Hum Mol Genet 18: 440-453.
31. Rong R, Jin W, Zhang J, Sheikh MS, Huang Y (2004) Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 23: 8216-8230.
32. Pirollo KF, Rait A, Zhou Q, Zhang XQ, Zhou J, et al. (2008) Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res 14: 2190-2198.
33. Di Benedetto M, Pineau P, Nouet S, Berhouet S, Seitz I, et al. (2006) Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma. Mol Cell Endocrinol 252: 207-215.
34. Aoki K, Taketo MM (2007) Adenomatous polyposis coli (APC): a multifunctional tumor suppressor gene. J Cell Sci 120: 3327-3335.
35. Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, et al. (2001) FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci U S A 98: 10374-10379.
36. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, et al. (2004) The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6: 129-137.
37. Warner SL, Gray PJ, Von Hoff DD (2006) Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol 33: 436-448.
38. Huszar D, Theoclitou ME, Skolnik J, Herbst R (2009) Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28: 197-208.